• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Eliminating atherosclerotic cardiovascular disease residual risk.

作者信息

Makover Michael E, Surma Stanislaw, Banach Maciej, Toth Peter P

机构信息

New York University Grossman School of Medicine, 12 Dunster Road, Great Neck, New York, NY 11021, USA.

Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medyków 18, Katowice 40-752, Poland.

出版信息

Eur Heart J. 2023 Dec 1;44(45):4731-4733. doi: 10.1093/eurheartj/ehad446.

DOI:10.1093/eurheartj/ehad446
PMID:37448228
Abstract
摘要

相似文献

1
Eliminating atherosclerotic cardiovascular disease residual risk.消除动脉粥样硬化性心血管疾病的残余风险。
Eur Heart J. 2023 Dec 1;44(45):4731-4733. doi: 10.1093/eurheartj/ehad446.
2
Letter by Koh Regarding Articles, "Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Population: The China-PAR Project (Prediction for ASCVD Risk in China)" and "Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population".科关于文章《预测中国人群动脉粥样硬化性心血管疾病的10年风险：中国-PAR项目（中国动脉粥样硬化性心血管疾病风险预测）》及《二级预防人群复发性血管事件估计10年风险及残余风险分布》的信函
Circulation. 2017 Mar 28;135(13):e818-e819. doi: 10.1161/CIRCULATIONAHA.116.026360.
3
Comprehensive risk management for the prevention of cardiovascular disease: executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -- 2012.预防心血管疾病的综合风险管理：日本动脉粥样硬化协会（JAS）日本动脉粥样硬化性心血管疾病诊断与预防指南——2012年执行摘要
J Atheroscler Thromb. 2013;20(7):603-15. doi: 10.5551/jat.15867. Epub 2013 Jul 25.
4
Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease.降低残余心血管风险的潜力：2型糖尿病和动脉粥样硬化性心血管疾病VERTIS CV人群中使用二十碳五烯酸乙酯的适用性。
Diabetes Obes Metab. 2023 May;25(5):1398-1402. doi: 10.1111/dom.14965. Epub 2023 Feb 14.
5
Residual cardiovascular risk among people with diabetes.糖尿病患者的残余心血管风险。
Diabetes Obes Metab. 2019 Apr;21 Suppl 1:28-38. doi: 10.1111/dom.13646.
6
Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.日本动脉粥样硬化协会（JAS）2017年动脉粥样硬化性心血管疾病预防指南。
J Atheroscler Thromb. 2018 Sep 1;25(9):846-984. doi: 10.5551/jat.GL2017. Epub 2018 Aug 22.
7
[Comments for 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults].[2013年美国心脏病学会/美国心脏协会降低成人动脉粥样硬化性心血管疾病风险的血液胆固醇治疗指南评论]
Zhonghua Nei Ke Za Zhi. 2015 Jan;54(1):9-12.
8
Treatment A) lifestyle modification: executive summary of the Japan Atherosclerosis Society(JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.治疗 A）生活方式改变：日本动脉粥样硬化协会（JAS）日本动脉粥样硬化性心血管疾病诊断与预防指南（2012 版）执行摘要
J Atheroscler Thromb. 2013;20(12):835-49. doi: 10.5551/jat.18820. Epub 2013 Oct 29.
9
[Some thoughts on the prevention and control of dyslipidemia and atherosclerotic cardiovascular disease in China].[关于中国血脂异常与动脉粥样硬化性心血管疾病防治的若干思考]
Zhonghua Nei Ke Za Zhi. 2014 Apr;53(4):257-8.
10
Cardiovascular disease in rheumatoid arthritis: Current perspectives on assessing and mitigating risk in clinical practice.类风湿关节炎中的心血管疾病：临床实践中评估与降低风险的当前观点
Best Pract Res Clin Rheumatol. 2015 Aug-Dec;29(4-5):597-613. doi: 10.1016/j.berh.2015.09.003. Epub 2015 Nov 18.

引用本文的文献

1
A holistic approach to managing cardio-kidney metabolic syndrome: insights and recommendations from the Italian perspective.管理心肾代谢综合征的整体方法：来自意大利视角的见解与建议
Front Cardiovasc Med. 2025 Apr 8;12:1583702. doi: 10.3389/fcvm.2025.1583702. eCollection 2025.
2
Rosuvastatin-based combination treatment with acetylsalicylic acid or ezetimibe in the management of patients at high and very high cardiovascular risk. Expert opinion paper of the Polish Lipid Association 2025.基于瑞舒伐他汀联合乙酰水杨酸或依折麦布治疗高心血管风险和极高心血管风险患者。波兰脂质协会2025年专家意见书
Arch Med Sci. 2025 Jan 7;21(1):1-15. doi: 10.5114/aoms/199826. eCollection 2025.
3
High-Density Lipoprotein Biomimetic Inorganic-Organic Composite Nanosystem for Atherosclerosis Therapy.
用于动脉粥样硬化治疗的高密度脂蛋白仿生无机-有机复合纳米系统
Polymers (Basel). 2025 Feb 26;17(5):625. doi: 10.3390/polym17050625.
4
Impact of surrogates for insulin resistance on mortality and life expectancy in primary care: a nationwide cross-sectional study with registry linkage (LIPIDOGRAM2015).基层医疗中胰岛素抵抗替代指标对死亡率和预期寿命的影响：一项基于全国登记数据链接的横断面研究（LIPIDOGRAM2015）
Lancet Reg Health Eur. 2024 Dec 12;49:101182. doi: 10.1016/j.lanepe.2024.101182. eCollection 2025 Feb.
5
Reaping the rewards of a simplified dosing regimen.收获简化给药方案的益处。
Eur Heart J Cardiovasc Pharmacother. 2025 Jan 11;10(8):694-696. doi: 10.1093/ehjcvp/pvae073.
6
Aggressive low-density lipoprotein (LDL) lowering for primary prevention: still an elusive goal.积极降低低密度脂蛋白（LDL）用于一级预防：仍然难以实现的目标。
Lipids Health Dis. 2024 Sep 6;23(1):285. doi: 10.1186/s12944-024-02280-0.
7
It is time to address the contribution of cholesterol in all apoB-containing lipoproteins to atherosclerotic cardiovascular disease.现在是时候探讨所有含载脂蛋白B的脂蛋白中的胆固醇对动脉粥样硬化性心血管疾病的作用了。
Eur Heart J Open. 2024 Jul 29;4(4):oeae057. doi: 10.1093/ehjopen/oeae057. eCollection 2024 Jul.
8
Position Statement of the Italian Society of Cardiovascular Prevention (SIPREC) and Italian Heart Failure Association (ITAHFA) on Cardiac Rehabilitation and Protection Programs as a Cornerstone of Secondary Prevention after Myocardial Infarction or Revascularization.意大利心血管预防学会（SIPREC）和意大利心力衰竭协会（ITAHFA）关于心肌梗死后或血运重建后心脏康复和保护计划作为二级预防基石的立场声明。
High Blood Press Cardiovasc Prev. 2024 Sep;31(5):417-423. doi: 10.1007/s40292-024-00663-z. Epub 2024 Jul 26.
9
Evolving Concepts of the SCORE System: Subtracting Cholesterol from Risk Estimation: A Way for a Healthy Longevity?SCORE系统的演变概念：从风险评估中减去胆固醇：实现健康长寿的一种方式？
Life (Basel). 2024 May 24;14(6):679. doi: 10.3390/life14060679.
10
2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders.波兰实验室诊断学会和波兰脂质协会2024年脂质代谢紊乱实验室诊断指南。
Arch Med Sci. 2024 Mar 18;20(2):357-374. doi: 10.5114/aoms/186191. eCollection 2024.